Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
debio0932 + cisplatin + gemcitabine
- Development stage
- Discontinued
- Lead developer
- Debiopharm
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
**debio0932 + cisplatin + gemcitabine** is a combination therapy under investigation for the treatment of advanced non-small cell lung cancer (NSCLC). Debio 0932 is an oral second-generation heat shock protein 90 (HSP90) inhibitor with demonstrated anti-tumor activity in preclinical models and early clinical trials. Cisplatin and gemcitabine are standard chemotherapy agents used in NSCLC. The combination aims to enhance efficacy by targeting multiple oncogenic pathways—Debio 0932 inhibits HSP90, leading to degradation of client proteins involved in tumor growth and survival, while cisplatin and gemcitabine act as cytotoxic chemotherapies[1][4][5].
- Other names
- Debio-0932 + cisplatin + gemcitabine
02
Targets
HSP90 (Heat shock protein 90 chaperone complex)RNR (Ribonucleotide reductase)Pt-DNA adduct (DNA-oxaliplatin adduct)HSP90AA1 (Heat shock protein HSP90-alpha)
Beyond the preview
Go deeper on debio0932 + cisplatin + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on debio0932 + cisplatin + gemcitabine.